JP2013510832A5 - - Google Patents

Download PDF

Info

Publication number
JP2013510832A5
JP2013510832A5 JP2012538360A JP2012538360A JP2013510832A5 JP 2013510832 A5 JP2013510832 A5 JP 2013510832A5 JP 2012538360 A JP2012538360 A JP 2012538360A JP 2012538360 A JP2012538360 A JP 2012538360A JP 2013510832 A5 JP2013510832 A5 JP 2013510832A5
Authority
JP
Japan
Prior art keywords
par
antagonist
influenza
patient
treatment
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2012538360A
Other languages
English (en)
Japanese (ja)
Other versions
JP2013510832A (ja
Filing date
Publication date
Priority claimed from EP09306098A external-priority patent/EP2335717A1/en
Application filed filed Critical
Publication of JP2013510832A publication Critical patent/JP2013510832A/ja
Publication of JP2013510832A5 publication Critical patent/JP2013510832A5/ja
Pending legal-status Critical Current

Links

JP2012538360A 2009-11-16 2010-11-15 Ａ型インフルエンザウイルス感染症の治療または予防用のｐａｒ−１アンタゴニスト Pending JP2013510832A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP09306098A EP2335717A1 (en) 2009-11-16 2009-11-16 PAR-1 antagonists for use in the treatment or prevention of influenza virus type a infections
EP09306098.6 2009-11-16
PCT/EP2010/067516 WO2011058183A1 (en) 2009-11-16 2010-11-15 Par-1 antagonists for use in the treatment or prevention of influenza virus type a infections

Publications (2)

Publication Number Publication Date
JP2013510832A JP2013510832A (ja) 2013-03-28
JP2013510832A5 true JP2013510832A5 (https=) 2013-12-26

Family

ID=41728318

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2012538360A Pending JP2013510832A (ja) 2009-11-16 2010-11-15 Ａ型インフルエンザウイルス感染症の治療または予防用のｐａｒ−１アンタゴニスト

Country Status (8)

Country Link
US (2) US8802623B2 (https=)
EP (2) EP2335717A1 (https=)
JP (1) JP2013510832A (https=)
KR (1) KR20120098696A (https=)
CN (1) CN102711787A (https=)
AU (1) AU2010317917B2 (https=)
CA (1) CA2780835A1 (https=)
WO (1) WO2011058183A1 (https=)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20140378502A1 (en) * 2011-05-12 2014-12-25 UNIVERSITé LAVAL Par1 Inhibitors for Use in the Treatment or Prevention of Paramyxoviridae Infections
WO2013070256A2 (en) * 2011-11-07 2013-05-16 The Scripps Research Institute Protease activated receptor-1 (par1) derived cytoprotective polypeptides and related methods
JP2016520570A (ja) * 2013-04-22 2016-07-14 アンスティテュ ナシオナル ドゥ ラ ルシェルシュ アグロノミックＩｎｓｔｉｔｕｔ Ｎａｔｉｏｎａｌ Ｄｅ Ｌａ Ｒｅｃｈｅｒｃｈｅ Ａｇｒｏｎｏｍｉｑｕｅ Ａ型インフルエンザウイルス感染の治療又は予防に使用するためのｐａｒ−４アンタゴニスト
HK1225386A1 (zh) 2013-09-25 2017-09-08 沃泰克斯药物股份有限公司 用作par-2信號傳導途徑抑制劑的咪唑並噠嗪類
WO2015124570A1 (en) * 2014-02-18 2015-08-27 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and pharmaceutical composition for the treatment of influenza a virus infection
CN107106632A (zh) * 2014-12-29 2017-08-29 中央研究院 一种治疗a型流感病毒感染的方法
CN116999558B (zh) * 2023-10-07 2024-01-02 中国人民解放军军事科学院军事医学研究院 Par1作为用于治疗或者抑制埃博拉病毒的靶点的应用

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4683202A (en) 1985-03-28 1987-07-28 Cetus Corporation Process for amplifying nucleic acid sequences
US5688768A (en) 1991-02-19 1997-11-18 Cor Therapeutics, Inc. Recombinant thrombin receptor and related pharmaceuticals
CA2131389A1 (en) 1992-03-02 1993-09-16 John M. Maraganore Thrombin receptor antagonists
IL106197A (en) 1992-07-30 1999-11-30 Cor Therapeutics Inc Agagonists for the rhombin receptors and pharmaceutical preparations containing them
US5854033A (en) 1995-11-21 1998-12-29 Yale University Rolling circle replication reporter systems
US6017890A (en) 1998-02-19 2000-01-25 Ortho-Mcneil Pharmaceutical, Inc. Azole peptidomimetics as thrombin receptor antagonists
US6630451B1 (en) * 1999-06-29 2003-10-07 Orthomcneil Pharmaceutical, Inc. Benzimidazolone peptidometics as thrombin receptor antagonist
GB0213286D0 (en) 2002-06-10 2002-07-24 Univ Edinburgh Par-2-Activating peptide derivative and pharmaceutical composition using the same
US8563511B2 (en) * 2004-10-06 2013-10-22 University Of Rochester Treatment of pulmonary hypertension using an agent that inhibits a tissue factor pathway
JP2008525468A (ja) * 2004-12-22 2008-07-17 エモリー・ユニバーシティ ポストコンディショニング臓器保護作用を増強する治療補助薬
US20080318960A1 (en) 2005-05-26 2008-12-25 Ethan Burstein PAR2-modulating compounds and their use
US20070123508A1 (en) 2005-05-27 2007-05-31 Roger Olsson PAR2-modulating compounds and their use
SI2242740T1 (sl) * 2008-02-05 2013-03-29 Sanofi SF5-derivati kot PAR1 inhibitorji, njihova priprava in uporaba kot zdravila
EP2427205A2 (en) 2009-05-04 2012-03-14 INSERM - Institut National de la Santé et de la Recherche Médicale Par2 agonists for use in the treatment or prevention of influenza virus type a infections

Similar Documents

Publication Publication Date Title
JP2013510832A5 (https=)
ECSP24034690A (es) Formulación tópica para un inhibidor de jak
JP2013542247A5 (https=)
ME02400B (me) Policiklična karbamoilpiridonska jedinjenja i njihova farmaceutska upotreba
JP2011528713A5 (https=)
JP2012255026A5 (https=)
BR112013032122A2 (pt) liberação modificada de 4-metil-3-[[4-(3-piridinil)-2-pirimidinil]amino]-n-[5-(4-metil-1h-imidazol-1-il)-3-(trifluorometil)fenil] benzamida solubilizada usando ácidos orgânicos
JP2010222367A5 (https=)
ME02547B (me) Inhibitori hepatitis c virusa
CL2014000492A1 (es) Compuestos derivados de n-[3-(1,2,4-oxadiazol-(5-il/amino/carbamoil)fenil]imidazo[1,2-a]pirdina-3-carboxamida, inhibidores de la quinasa c-kit; composicion farmaceutica; y su uso para el tratamiento de la enfermedad de alzheimer, artritis, aterosclerosis, entre otras
CL2007003742A1 (es) Compuestos derivados heterociclicos, inhibidores de protein quinasas activadas por mitogenos; proceso de preparacion; composicion farmaceutica; articulo de manufactura; y uso para el tratamiento de enfermedades tales como trastornos hiperproliferativ
JP2014521735A5 (https=)
EA201400358A1 (ru) Замещенные n-[1-циано-2-(фенил)этил]-2-азабицикло[2.2.1]гептан-3-карбоксамидные ингибиторы катепсина с
JP2013534248A5 (https=)
CL2007003690A1 (es) Compuestos derivados de 1-azonia-biciclo[2.2.2]octano; proceso de preparacion; composicion farmaceutica; y uso en el tratamiento de enfermedades pulmonares obstructivas cronicas.
WO2009033732A3 (en) Use of the peptide phpfhlfvy (renin inhibitor) as a therapeutic agent
EP2753348A4 (en) PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OF CANCER WITH AN INTERFERON ALPHA CONJUGATE
BR112014006356A2 (pt) nova composição farmacêutica resistente ao abuso para o tratamento de dependência de opioide
CL2013001591A1 (es) Compuestos derivados de triazolopiridina; inhibidores de pde10a; proceso de obtencion; composicion farmaceutica; y uso en el tratamiento o profilaxis de trastornos psicoticos, esquizofrenia, ansiedad, entre otras enfermedades.
JP2012505883A5 (https=)
CL2007003346A1 (es) Compuestos derivados de 2,5-dihidro-3h-pirazolo[4,3-c]piridazin-3-ona; procedimiento de preparacion; compuestos intermediarios; composicion farmaceutica; y uso en el tratamiento de enfermedades tales como sindrome de abstinencia a una sustancia, tras
JP2016539156A5 (https=)
JP2016516074A5 (https=)
JP2016507547A5 (https=)
JO3122B1 (ar) مشتقات إسترا-5،3،1(10)، 16- تترايين-3- كربوكساميد، عمليات لتحضيرها، مستحضرات دوائية تشتمل عليها واستخدامها لتحضير أدوية